Posted by on May 2, 2018 9:07 am
Categories: Uncategorized

Source: Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics

HAMBURG, Germany–()–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
today announced that it has expanded its CRISPR service offering with
the addition of a licence from ERS Genomics Limited. With this licence,
Evotec gains access to the leading technology for gene editing, thereby
complementing and expanding its existing service offering in the CRISPR
gene editing space.

The new licence from ERS Genomics Limited complements and expands
Evotec’s existing CRISPR licences through the Broad Institute with gene
editing technology from Emmanuelle Charpentier and others.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented:
“Obtaining this new licence from ERS Genomics is the latest example of
Evotec’s investment in gene editing technologies. Together with our
world-leading iPSC and phenotypic screening platforms, the continued
expansion of CRISPR-based technologies at Evotec provides our partners
with a unique solution for the identification of novel disease modifying

Eric Rhodes, CEO of ERS, commented: “We’re thrilled to add Evotec to our
growing list of licensees of CRISPR-Cas9 technology. As one of the
world’s leading providers of customised research solutions it’s very
gratifying to see Evotec actively expanding its use of the technology
across several key areas.”

About Evotec’s CRISPR offering CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats) is a naturally occurring bacterial immune
system. Researchers have harnessed this system as a genome editing tool
for mammalian cells. Evotec has multiple licences to this technology
through ERS Genomics and the Broad Institute for the use of the
CRISPR-Cas9 gene editing technology.

Evotec uses the CRISPR technology to drive its target identification
platform as well as aid the deconvolution of targets from phenotypic
screening. With the integration of genome-wide arrayed CRISPR libraries
into Evotec’s screening platforms, Evotec is harnessing the power of
gene deletion and human, cell-based disease models to identify novel
targets for downstream drug discovery programmes.


ERS Genomics was formed to provide broad access to the foundational
CRISPR/Cas9 intellectual property held by Dr Emmanuelle Charpentier.
Non-exclusive licences are available for research and sale of products
and services across multiple fields including: research tools, kits,
reagents; discovery of novel targets for therapeutic intervention; cell
lines for discovery and screening of novel drug candidates; GMP
production of healthcare products; production of industrial materials
such as enzymes, biofuels and chemicals; and synthetic biology. For
additional information please visit


AG Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product approaches
with leading pharmaceutical and biotechnology companies, academics,
patient advocacy groups and venture capitalists. We operate worldwide
providing the highest quality stand-alone and integrated drug discovery
solutions, covering all activities from target-to-clinic to meet the
industry’s need for innovation and efficiency in drug discovery (EVT
Execute). The Company has established a unique position by assembling
top-class scientific experts and integrating state-of-the-art
technologies as well as substantial experience and expertise in key
therapeutic areas including neuroscience, infectious diseases, diabetes
and complications of diabetes, pain, inflammation, and oncology and. On
this basis, Evotec has built a broad and deep pipeline of more than 80
partnered product opportunities at clinical, pre-clinical and discovery
stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi and UCB
and development partnerships with e.g. Sanofi in the field of diabetes,
Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information, please go to
and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements.
We expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances on
which any such statement is based.

Language: English
Company: Evotec AG Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222


ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated
Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich,
Stuttgart, Tradegate Exchange

Published at Wed, 02 May 2018 06:26:00 +0000

Leave a Reply